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Cardiovascular shock due to verapamil intoxication is often refractory to standard resuscitation methods. Recommended therapy
includes prevention of further absorption of the drug, inotropic therapy, calcium gluconate, and hyperinsulinemia/euglycemia
therapy. Often further measures are needed such as ventricular pacing or mechanical circulatory support. Still, mortality remains
high. Levosimendan, an inotropic agent, that enhances myoﬁlament response to calcium, increases myocardial contraction and
could therefore be beneﬁcial in verapamil intoxication. Here, we report the case of a 60-year-old patient with clinically severe
verapamil poisoning who presented with shock, bradycardia, and sopor. Standard therapy including high-dose inotropes failed
to ameliorate the signs of intoxication. But additional therapy with levosimendan led to rapid improvement. Based on this
observation, the literature is reviewed focusing on utilization of levosimendan in the treatment of calcium channel blocker
overdose. We suggest to consider levosimendan as additional treatment option in patients with cardiovascular shock due to
verapamil intoxication that are refractory to standard management.
1.Introduction
Verapamil antagonizes L-type calcium channels and thereby
inhibits calcium inﬂux into myocardial and vascular tissue.
The negative inotropic and chronotropic eﬀects of vera-
pamil may result in bradycardia, decreased cardiac output,
vasodilation of smooth vascular muscle, and cardiovascular
collapse [1]. Calcium channel blockers also inhibit the inﬂux
of calcium into pancreatic beta cells. This leads to reduced
insulin secretion and hyperglycemia [2]. In consideration of
these eﬀects, treatment of calcium channel blocker overdose
includesvolumeapplication,intravenouscalciumtoincrease
calcium availability, inotropic therapy, and hyperinsulinemic
euglycemia therapy [3]. Even with extensive conventional
treatment, requiring high doses of inotropic therapy [4–
11], additional invasive therapies such as pacemaker therapy
[5, 9, 10] or IABP insertion [10] are necessary in severe cases
to stabilize hemodynamics. However, mortality remains high
[12].
Levosimendan, an inotropic agent, acts as a calcium
sensitizer and increases the association rate of myosin actin
cross-bridges and slows down their dissociation rate by
binding to troponin c [13] .I t si m p a c ti sc a l c i u md e p e n d e n t
[13, 14]. Levosimendan also exhibits vasodilation via ATP-
sensitive potassium channels in vascular smooth-muscle
cells, and recently it also has been shown to act on
mitochondrial ATP-sensitive potassium channels [15]. The
mechanism is believed to be responsible for its cardiopro-
tective properties in reversing myocardial stunning [15].
The positive inotropic eﬀect of levosimendan seems to be
preserved with acidosis [16].
Levosimendan has been successfully used in the setting
of acute myocardial failure following myocardial infarction
with few side eﬀects [17, 18].
Based on these observations, in theory, levosimendan
has the potential to be beneﬁcial in the cardiovascular
compromise caused by verapamil overdose.
2. Case Presentation
Here, we present the case of a 60-year-old male patient that
was conducted to hospital with the suspicion of cardiogenic
shock.2 Case Reports in Medicine
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Figure 1: Vital signs in relation to levosimendan application. ABP: arterial blood pressure; NBP: non-invasive blood pressure.
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Figure 2: ECG changes in relation to levosimendan adminstration.
Paramedics were called for a patient, who had treated
himself with 6 tablets of verapamil 80mg within a period
of 6 hours for palpitations. He had a history of intermit-
tent supraventricular tachycardia and therefore had been
prescribed verapamil as needed. The patient was con-
scious, blood pressure was 91/51mmHg, and the pulse
was 46bpm. The patient received isotonic crystalloids and
1mg of atropine with no change in heart rate during the
transport. Upon arrival at the emergency department, vital
signs included blood pressure of 98/79mmHg, pulse of
41bpm, respiratory rate of 20/min and temperature of 36.1
degree Celsius. The ECG showed sinus arrest and a wide
QRS complex. Immediately, the patient was given isotonic
crystalloids, calcium gluconate 10% (1g) intravenously, and
70U of insulin in dextrose. A transthoracic echocardiog-
raphy showed diﬀuse hypokinesia with a slightly reduced
ejection fraction. Blood pressure and pulse declined to
70/32mmHg and 35bpm, respectively, while the patient
became soporous. A bolus of 50μg of epinephrine was
given, and an epinephrine infusion was started at a rate of
20μg/min. The patient was admitted to the intensive care
unit, where a central venous catheter and a femoral arterial
line were inserted. Bradycardia, hypotension, ECG changes,
and sopor persisted despite continued calcium gluconate
administration, hyperinsulinemia/euglycemia therapy, and
inotropic therapy with epinephrine.
Because of primary failure of standard therapy in this
clinically severe calcium antagonist intoxication, levosimen-
dan was added to treatment.
A levosimendan loading dose of 24μg/kg was followed
by a levosimendan infusion at a rate of 0.1μg/kg/h. Within
minutesthepulserateincreasedsteadilyto60bpm(Figure 1)
withreappearanceofsinusnodeactivityintheECGandnor-
malizationoftheQRSwidth(Figure 2).Thepatientregained
consciousness but remained hypotensive. Levosimendan was
continued for 24 hours. Blood pressure ﬁnally stabilized,
and epinephrine could be tapered 9 hours after starting
levosimendan and stopped after 16 hours. The patient was
transferred to the ward after 30 hours and discharged on
day 5.
3. Discussion
We report a case of verapamil overdose-induced cardio-
genic shock. Our patient was resuscitated with conven-
tional treatment including calcium gluconate i.v., hyperin-
sulinemia/euglycemia therapy, and inotropic therapy with
epinephrine according to current recommendations. How-
ever, his clinical status, hemodynamics, and ECG alterations
did not improve until initiation of levosimendan. Within 15
minutes of infusing the loading dose, the patient regained
consciousness, and the pulse rate increased to 60bpm.
ConversiontonormofrequentsinusrhythmandstabilisationCase Reports in Medicine 3
of blood pressure were achieved during the following 16
hours of continued combined therapy with epinephrine and
levosimendan.
In a rodent model of verapamil toxicity levosimendan
increased cardiac output; however blood pressure remained
low [19]. Hypotension in our patient may have been main-
tained by levosimendan’s agonistic properties on peripheral
vascular K(+)(ATP) channels [19].
In another rat model of verapamil toxicity levosimendan
did not improve survival; however it was used as a unique
antidote [20]. This may be attributed to levosimendan
ability to exacerbate the hypotension induced by verapamil
intoxication [20].
Although direct evidence is missing, in two reported
cases of calcium channel overdose hemodynamics did not
improve despite extensive conventional treatment until ini-
tiation of levosimendan [10].
In the case of our patient, the beneﬁcial eﬀect is quite
suggestive. First, the heart rate rose simultaneously with
application of levosimendan. Second, the patient regained
consciousness, despite prolonged hypotension, presumably
due to improved organ perfusion. Last, sinus node activity
resumeduponinitiationoflevosimendantherapy,suggesting
a beneﬁcial therapeutic eﬀect on not only the contractile
function but also cardiac electrophysiology.
4. Conclusions
There is no direct evidence from the literature that levosi-
mendan counteracts the hemodynamic compromise caused
by verapamil overdose in humans. However, a beneﬁcial
eﬀect is suggestive. In conclusion, levosimendan should be
considered as an additional treatment option in verapamil
intoxication if standard therapy is insuﬃcient to stabilize
hemodynamics.
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